Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Carlsmed (CARL) Shares Issued (2024 - 2026)

Carlsmed filings provide 2 years of Shares Issued readings, the most recent being $93.3 million for Q4 2025.

On a quarterly basis, Shares Issued rose 1332485.71% to $93.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $93.3 million, a N/A change, with the full-year FY2025 number at $93.5 million, up 274797.06% from a year prior.
Shares Issued hit $93.3 million in Q4 2025 for Carlsmed, up from $1000.0 in the prior quarter.
In the past five years, Shares Issued ranged from a high of $93.3 million in Q4 2025 to a low of $1000.0 in Q3 2025.